Prenetics (PRE) Q2 2026 earnings review
Hyper-Growth Secured by New Capital, But Operating Burn is Deep
Prenetics is operating at two speeds. On the top line, the IM8 brand is an undeniable rocketship: Total revenue surged 288% YoY to $46.5M, driven almost entirely by IM8 ($45.0M). The company raised FY26 guidance to $220-230M and introduced a massive $400M+ target for 2027. However, buying this growth is expensive. Adjusted EBITDA loss widened dramatically to $19.0M as acquisition marketing doubled. A new $1B funding facility from General Catalyst flips the script on cash flow, moving the company to Adjusted Free Cash Flow positive in July, but the core operating profitability remains a distant, deliberate choice rather than a current reality.
🐂 Bull Case
July marked the first month of positive consolidated Adjusted Free Cash Flow, fueled by a $1B non-dilutive facility from General Catalyst that covers up to 70% of marketing spend. The company is now self-funding its explosive growth.
Despite doubling acquisition marketing spend to $35.7M in Q2, CAC actually decreased slightly from $305 to $301, and preliminary July data shows a further drop to $239. This implies massive organic brand momentum.
🐻 Bear Case
Adjusted EBITDA loss collapsed to $19.0M from $5.6M in Q1. The $9.0M net loss looks artificially better due to $10M in non-operating fair value gains on digital assets and warrants, masking the heavy cost of core operations.
The CircleDNA segment is in terminal decline, shrinking 33% YoY to just $1.48M. It is now a negligible and fading part of the business.
⚖️ Verdict: 🟢
Bullish. The widening EBITDA loss is a feature, not a bug, of their current strategy. By securing $1B in non-dilutive financing to cover CAC, Prenetics has removed the cash-burn constraint that typically kills hyper-growth DTC brands, allowing them to capture market share aggressively while cohorts pay themselves back.
Key Themes
General Catalyst Facility Changes the Math
The $1B Customer Value Fund facility from General Catalyst fundamentally alters the company's risk profile. By financing up to 70% of monthly marketing spend against cohort returns (which are currently returning $1.52 on the dollar), Prenetics shifted from burning its own equity cash to utilizing structured growth capital. This specific mechanic is the sole reason Adjusted FCF turned positive in July.
Quarterly Subscriptions Driving LTV
Accelerating. The shift to quarterly subscriptions is paying off immensely. Quarterly plans crossed monthly plans in March and represented 54.8% of July revenue. This drives first-month billings per new customer to roughly $212 (July cohort) versus the 2025 average of $142, compressing the payback period and locking in recurring revenue.
CircleDNA is a Laggard Segment
Decelerating. While IM8 acts as a rocketship, the legacy CircleDNA business continues to erode. Revenue fell to $1.48M in Q2 2026 from $2.17M in Q1 and $2.21M a year ago. It now represents barely 3% of total revenues. Management's focus is entirely on IM8, making CircleDNA an irrelevant asset that continues to drag slightly on overall metrics.
EBITDA Loss Contradicts the 'Positive FCF' Headline
While management proudly touts positive Adjusted FCF in July, core operations are bleeding heavily. Q2 Adjusted EBITDA loss was $19.0M, drastically worse than the GAAP net loss of $9.0M. The GAAP number was artificially inflated by $10.0M in net fair value gains (digital assets and warrants). The underlying reality is that selling and marketing expenses hit $41.3M against $46.5M in total revenue. If cohort retention drops or the GC facility caps out, this burn rate is structurally dangerous.
Macro Repricing of the Supplement Category
Management explicitly tied their trajectory to recent massive macro M&A activity in the space: Unilever acquiring Grüns ($1.2B), Danone buying Huel ($1.1B), and P&G acquiring Thorne ($3.8B at 5.8x revenue). Prenetics is positioning IM8's subscription base and clinical evidence as matching the exact profile these strategics are paying multi-billion dollar premiums to acquire.
Clinical Trials Building a Defensible Moat
Prenetics is leaning heavily into scientific validation to separate IM8 from commodity supplements. They have three randomized, placebo-controlled trials underway, including a Mayo Clinic study on healthcare workers and a 180-person longevity study tracking hsCRP and HOMA-IR biomarkers. Results are expected in Q1 2027, which could provide a massive marketing catalyst.
Other KPIs
Accelerating. Up from 64% in Q1 and 62% in Q2 2025. IM8 specifically hit 65% (up from 57% a year ago). This 800 bps expansion was achieved despite scaling revenue 4.6x, driven by manufacturing volumes, shipping density, and favorable product mix.
Stable. The company ended Q2 with $59.1M in cash and equivalents plus $50.3M in current financial assets, with zero debt. This is impressive considering they executed a $40M share repurchase program while funding the heaviest acquisition quarter in their history.
Accelerating. Up from ~82,000 active subscribers reported in Q1. Roughly 87% of all revenue is now recurring, providing high visibility into future quarters and validating the LTV models underpinning the General Catalyst debt facility.
Guidance
Accelerating. The $63.5M midpoint implies +36.5% sequential growth over Q2 2026, and a staggering +170% YoY growth compared to Q3 2025 ($23.5M). IM8 is expected to contribute $61.5-$62.5M of this total.
Accelerating. Raised from previous guidance. The IM8 component was raised to $215-$222M (up from $190-$210M). The top end implies a Q4 2026 run-rate of ~$81M, which would be 3x the size of Q4 2025.
Accelerating. Initiated early guidance signaling massive confidence. Management notes that because 87% of revenue is recurring and cohorts retain consistently, a substantial portion of this $400M is already 'on the books' from current subscribers.
Reversing. A significant improvement from the $(24.6)M Adjusted EBITDA loss in 1H 2026. This halving of the burn rate reflects the maturing of early cohorts starting to throw off cash, balancing out the heavy upfront CAC investments.
Key Questions
General Catalyst Facility Caps
The CVF facility finances up to 70% of marketing spend and takes a 'capped share of income.' What exactly is the multiple on that cap, and how does it impact gross margin recognition on mature cohorts?
CircleDNA Wind Down
With CircleDNA revenue continuing to shrink and management's focus 100% on IM8, is there a plan to formally divest or wind down the legacy genetics business to eliminate administrative drag?
Channel Diversification Updates
In Q1, you discussed testing TikTok, YouTube, and AppLovin to reduce the 85% dependency on Meta. Did these new channels contribute to the falling CAC observed in July, or is Meta simply performing better?
Warrant Overhang
You noted 2.36M Class C Warrants at an $18 strike price and a forced-exercise right if shares trade above $21.60. How does management plan to message this potential near-term dilution event to retail shareholders?